Thermo Fisher Scientific has received clearance from Sweden's Competition and Markets Authority (CMA) for the acquisition of Olink Holding, valued at USD 3.1 billion. The clearance was given after the completion of CMA's investigations, which commenced in May 2024 after the initial inquiry.
Post-acquisition, Thermo Fisher Scientific will gain rights to Olink’s protein analysis assays, which can be run on laboratories’ installed qPCR instruments and next-generation sequencers. It will also gain rights to Olink's international operations, which are based in Boston, Tokyo, and Shanghai.
Analyst QuickTake: The initial offer for the acquisition was made on October 17, 2023 , with the company agreeing to purchase all Olink’s outstanding Nasdaq shares for USD 26 per share. The offer was set to expire on April 30, 2024, and was postponed to July 08, 2024, after multiple extensions.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.